Statistically Justifiable Visible Residue Limits - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Statistically Justifiable Visible Residue Limits
Current methods for establishing visible residue limits (VRLs) are not statistically justifiable. The author proposes a method for estimating VRLs based on logistic regression.

Pharmaceutical Technology
Volume 34, Issue 3, pp. 58-71


Logistic regression was demonstrated to be a better approach than the current method for estimating accurate and statistically justifiable VRLs based on discrete responses. It has the advantage of always making biologically meaningful predictions and, in most cases, its predictions closely reflect observations. Logistic regression should be used to determine VRLs rather than current method. Because the model may provide a much larger VRL than the current method does, the quality of visual inspection, in terms of the discrete response, can be improved by properly controlling the experimental variables and defining the acceptance criterion for the estimation of VRL.

Based on the modeling procedure, VRL can be defined as a scientifically justifiable residue concentration that, when viewed with the unaided eye, as measured by a specific method, would be detected by the observers with a predefined acceptance criterion. Once established, the VRL could then be used for CV and routine monitoring purposes. It would be appropriate to define the VC criterion as the absence of all particulate and nonparticulate contaminants above the established VRL from the surface when viewed with the unaided eye under preverified viewing conditions.

M. Ovais is a senior pharmaceutical scientist at Xepa-Soul Pattinson, 1-5, Cheng Industrial Estate, 75250 Melaka, Malaysia, tel. +60 63351515, fax +60 63355829,


1. PIC/S, "Recommendations on Validation Master Plan, Instal-lation and Operational Qualification, Non-Sterile Process Validation, Cleaning Validation," (PIC/S, Geneva, Aug. 2002).

2. PDA Pharmaceutical Cleaning Validation Task Force, PDA J. Pharm. Sci. Technol. 52 (6), 1–23 (1998).

3. W. Hall, J. Val. Technol. 14 (1), 42–49 (2007).

4. R.J. Forsyth, J. Hartman, and V. Van Nostrand, Pharm. Technol. 30 (9), 104–114 (2006).

5. R.J. Forsyth and J. Hartman, Pharm. Eng. 28 (3), 1–10 (2008).

6. European Chemical Industry Council, Guidance on Aspects of Cleaning Validation in Active Pharmaceutical Ingredient Plants, (CEFIC, Brussels, Dec. 2000)

7. G.L. Fourman and M.V. Mullen, Pharm. Technol. 17 (4), 54–60 (1993).

8. NASA, "Space Shuttle, Contamination Control Requirements (Lyndon B. Johnson Space Center, Houston, TX)," SN-C-0005, Rev. D, 1–3 (July 20, 1998).

9. D. A. LeBlanc, Pharm. Technol. 22 (10), 136–148 (1998).

10. R.J. Forsyth, V. Van Nostrand, and G. Martin, Pharm. Technol. 28 (10), 58–72 (2004).

11. R.J. Forsyth and V. Van Nostrand, Pharm. Technol. 29 (10), 152–161 (2005).

12. R.J. Forsyth and V. Van Nostrand, Pharm. Technol. 29 (4), 134–140 (2005).

13. G. Hutcheson and N. Sofroniou, "Logistic Regression," in The Multivariate Social Scientist: Introductory Statistics Using Generalized Linear Models (Sage Publications, London, 1st ed., 1999), pp. 113–152.

14. J.L. Fleiss, B. Levin, and M.C. Paik, "Logistic Regression," in Statistical Methods for Rates and Proportions, W.A. Shewart and S.S. Wilks, Eds. (John Wiley and Sons, Hoboken, NJ, 3rd ed., 2003), pp. 284–339.

15. F.Y. Hsieh, D.A. Bloch, and M.D. Larsen, Stat. Med. 17 (14), 1623–1634 (1998).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here